[A20-116] Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V

Last updated 04.06.2021

Project no.:
A20-116

Commission:
Commission awarded on 14.12.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitizing EGFR mutation or ALK translocation.

Result of dossier assessment:

PD-L1 expression (TPS) of at least 50 percent: added benefit not proven.

PD-L1 expression (TPS) below 50 percent: non-squamous histology: indication of added benefit; extent “non-quantifiable". Squamous histology: added benefit not proven.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2021.06.04 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.